All
Patient education, prudent prescribing foundation for safe antibiotic use for acne
January 1st 2007Philadelphia, Pa. - Oral antibiotic treatment for acne is generally very safe, but clinicians need to counsel patients about potentially serious adverse events and prescribe these agents judiciously in order to limit problems with bacterial resistance, says Guy F. Webster, M.D., Ph.D., clinical professor of dermatology, Jefferson Medical College, Thomas Jefferson University, here.
Sulfasalazine, dapsone: Good alternative options for treatment of chronic urticaria
January 1st 2007Philadelphia - In patients with chronic urticaria who do not respond to standard antihistamine treatment, the older drugs sulfasalazine and dapsone represent promising new treatment alternatives, Lisa A. Beck, M.D. said here at the 2006 meeting of the American College of Allergy, Asthma & Immunology (ACAAI).
Topical nitroglycerin gel shows promise as treatment advance for Raynaud's
January 1st 2007Washington - Results of a phase 3a laboratory study suggest that a novel topical nitroglycerin (NTG) gel (Vascana, MediQuest Therapeutics) has exciting potential as a safe and effective treatment alternative for patients with Raynaud's phenomenon, said Laura K. Hummers, M.D., at the annual meeting of the American College of Rheumatology here.
FDA warns about contrast agent
January 1st 2007Rockville, Md. - Patients with moderate to end-stage kidney disease who undergo an MRI or MRA with a gadolinium-based contrast agent may develop nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD), a new disease that may cause death, the Food and Drug Administration warns.
Study says mycosis fungoides responds well to biological - modifier therapies
December 5th 2006National report - According to a study published in the November issue of the Journal of the American Academy of Dermatology, interleukin-12 (IL-12) produces a partial response rate of 43 percent in patients with previously treated mycosis fungoides.
Animal tests show promise for new antibody technology that fights skin cancer
December 5th 2006San Francisco ? Officials of Pain Therapeutics Inc., a biopharmaceutical company based here, is reporting that a proof-of-concept animal study of its new antibody technology for the treatment of skin cancer has produced promising results.